Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9Y2T1
UPID:
AXIN2_HUMAN
Alternative names:
Axin-like protein; Axis inhibition protein 2; Conductin
Alternative UPACC:
Q9Y2T1; Q3MJ88; Q9H3M6; Q9UH84
Background:
Axin-2, also known as Axis inhibition protein 2, Conductin, and Axin-like protein, plays a pivotal role in the Wnt signaling pathway, a critical axis in cellular growth and differentiation processes. By down-regulating beta-catenin, Axin-2 facilitates its phosphorylation alongside APC by GSK3B, thus inhibiting Wnt signaling. This regulation is crucial for maintaining cellular homeostasis and preventing uncontrolled cell proliferation.
Therapeutic significance:
Axin-2's involvement in colorectal cancer and Oligodontia-colorectal cancer syndrome highlights its potential as a therapeutic target. The protein's role in the pathogenesis of these diseases, through its regulation of the Wnt signaling pathway, suggests that modulating its activity could offer new avenues for treatment. Understanding the role of Axin-2 could open doors to potential therapeutic strategies, particularly in combating colorectal cancer, where genetic alterations in the Wnt pathway are a common feature.